TY - JOUR
T1 - Mice heterozygous for CREB binding protein are hypersensitive to γ-radiation and invariably develop myelodysplastic/myeloproliferative neoplasm
AU - Zimmer, Stephanie N.
AU - Lemieux, Madeleine E.
AU - Karia, Bijal P.
AU - Day, Claudia
AU - Zhou, Ting
AU - Zhou, Qing
AU - Kung, Andrew L.
AU - Suresh, Uthra
AU - Chen, Yidong
AU - Kinney, Marsha C.
AU - Bishop, Alexander J.R.
AU - Rebel, Vivienne I.
N1 - Funding Information:
This work was supported with funding from the Greehey Children’s Cancer Research Institute, University of Texas Health Science Center at San Antonio, San Antonia, TX, USA (V.I.R.), National Institutes of Health (NIH)/National Cancer Institute (Bethesda, MD, USA; P30 CA054174-17 to Y.C. and the institutional flow cytometry core) and NIH/National Center for Research Resources (Bethesda, MD, USA; 1UL1RR025767 to Y.C.).
PY - 2012/4
Y1 - 2012/4
N2 - Myelodysplastic syndrome is a complex family of preleukemic diseases in which hematopoietic stem cell defects lead to abnormal differentiation in one or more blood lineages. Disease progression is associated with increasing genomic instability and a large proportion of patients go on to develop acute myeloid leukemia. Primarily a disease of the elderly, it can also develop after chemotherapy. We have previously reported that CREB binding protein (Crebbp) heterozygous mice have an increased incidence of hematological malignancies, and others have shown that CREBBP is one of the genes altered by chromosomal translocations found in patients suffering from therapy-related myelodysplastic syndrome. This led us to investigate whether hematopoietic tumor development in Crebbp+/- mice is preceded by a myelodysplastic phase and whether we could uncover molecular mechanisms that might contribute to its development. We report here that Crebbp+/- mice invariably develop myelodysplastic/myeloproliferative neoplasm within 9 to 12 months of age. They are also hypersensitive to ionizing radiation and show a marked decrease in poly(ADP-ribose) polymerase-1 activity after irradiation. In addition, protein levels of XRCC1 and APEX1, key components of base excision repair machinery, are reduced in unirradiated Crebbp+/- cells or upon targeted knockdown of CREBBP levels. Our results provide validation of a novel myelodysplastic/myeloproliferative neoplasm mouse model and, more importantly, point to defective repair of DNA damage as a contributing factor to the pathogenesis of this currently incurable disease.
AB - Myelodysplastic syndrome is a complex family of preleukemic diseases in which hematopoietic stem cell defects lead to abnormal differentiation in one or more blood lineages. Disease progression is associated with increasing genomic instability and a large proportion of patients go on to develop acute myeloid leukemia. Primarily a disease of the elderly, it can also develop after chemotherapy. We have previously reported that CREB binding protein (Crebbp) heterozygous mice have an increased incidence of hematological malignancies, and others have shown that CREBBP is one of the genes altered by chromosomal translocations found in patients suffering from therapy-related myelodysplastic syndrome. This led us to investigate whether hematopoietic tumor development in Crebbp+/- mice is preceded by a myelodysplastic phase and whether we could uncover molecular mechanisms that might contribute to its development. We report here that Crebbp+/- mice invariably develop myelodysplastic/myeloproliferative neoplasm within 9 to 12 months of age. They are also hypersensitive to ionizing radiation and show a marked decrease in poly(ADP-ribose) polymerase-1 activity after irradiation. In addition, protein levels of XRCC1 and APEX1, key components of base excision repair machinery, are reduced in unirradiated Crebbp+/- cells or upon targeted knockdown of CREBBP levels. Our results provide validation of a novel myelodysplastic/myeloproliferative neoplasm mouse model and, more importantly, point to defective repair of DNA damage as a contributing factor to the pathogenesis of this currently incurable disease.
UR - http://www.scopus.com/inward/record.url?scp=84862805858&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84862805858&partnerID=8YFLogxK
U2 - 10.1016/j.exphem.2011.12.004
DO - 10.1016/j.exphem.2011.12.004
M3 - Article
C2 - 22198154
AN - SCOPUS:84862805858
SN - 0301-472X
VL - 40
SP - 295-306.e5
JO - Experimental Hematology
JF - Experimental Hematology
IS - 4
ER -